Peptide receptor radionuclide therapy is a valid therapeutic option for pancreatic neuroendocrine neoplasms. The aim of this study was to describe an initial experience with the use of peptide receptor radionuclide therapy as a neoadjuvant agent for resectable or potentially resectable pancreatic neuroendocrine neoplasms
textabstractPeptide receptor radionuclide therapy (PRRT) has been shown to be an effective treatment...
Nuclear medicine plays a pivotal role in the management of patients affected by neuroendocrine neopl...
Evidence supporting the potential contribution of targeted radiotherapy to the management of neuroen...
Non-functional pancreatic neuroendocrine tumours (NETs) can present with advanced local or distant (...
A patient with advanced pancreatic neuroendocrine carcinoma and liver metastases underwent explorati...
The systemic treatment of patients with pancreatic neuroendocrine tumors is based on placebo-control...
This thesis focuses on peptide receptor-targeted therapies, with particular reference to the somatos...
Abstract. The incidence rate of pancreatic neuroendocrine tumors (panNET) is increasing continuously...
Purpose: Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE induces objective response...
Somatostatin receptor-targeting peptides are widely used for the imaging and therapy of neuroendocri...
Neuroendocrine tumors (NETs) are relatively rare tumors, mainly originating from the digestive syste...
Peptide receptor radionuclide therapy (PRRT) has been one of the most successful and exciting exampl...
Background: We evaluated the activity and safety profile of 177Lu-DOTATATE peptide receptor radionuc...
Peptide receptor radionuclide therapy (PRRT) is an established treatment of metastatic neuroendocrin...
textabstractPeptide receptor radionuclide therapy is a new treatment modality for patients with inop...
textabstractPeptide receptor radionuclide therapy (PRRT) has been shown to be an effective treatment...
Nuclear medicine plays a pivotal role in the management of patients affected by neuroendocrine neopl...
Evidence supporting the potential contribution of targeted radiotherapy to the management of neuroen...
Non-functional pancreatic neuroendocrine tumours (NETs) can present with advanced local or distant (...
A patient with advanced pancreatic neuroendocrine carcinoma and liver metastases underwent explorati...
The systemic treatment of patients with pancreatic neuroendocrine tumors is based on placebo-control...
This thesis focuses on peptide receptor-targeted therapies, with particular reference to the somatos...
Abstract. The incidence rate of pancreatic neuroendocrine tumors (panNET) is increasing continuously...
Purpose: Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE induces objective response...
Somatostatin receptor-targeting peptides are widely used for the imaging and therapy of neuroendocri...
Neuroendocrine tumors (NETs) are relatively rare tumors, mainly originating from the digestive syste...
Peptide receptor radionuclide therapy (PRRT) has been one of the most successful and exciting exampl...
Background: We evaluated the activity and safety profile of 177Lu-DOTATATE peptide receptor radionuc...
Peptide receptor radionuclide therapy (PRRT) is an established treatment of metastatic neuroendocrin...
textabstractPeptide receptor radionuclide therapy is a new treatment modality for patients with inop...
textabstractPeptide receptor radionuclide therapy (PRRT) has been shown to be an effective treatment...
Nuclear medicine plays a pivotal role in the management of patients affected by neuroendocrine neopl...
Evidence supporting the potential contribution of targeted radiotherapy to the management of neuroen...